3rd February 2020
Key Atheneum Experts
Former Commercial Director – AbbVie
Global Marketing Director – AbbVie
Former UK Country Manager – Allergen (rival)
Key Information
HQ – US
Operations – Global
AbbVie have responded to requests from Chinese health authorities to supply their Aluvia drug as a possible experimental option to solve the coronavirus crisis. In other news, Allergan have terminated a deal with AstraZeneca to clear a regulatory barrier to its pending merger with AbbVie. Share price fell 8.7% in the past 30 days and has remained steady over the past 52 weeks.
Key Atheneum Experts
Former Managing Director – GSK
Former Group Chief Information Security Officer – GSK
Marketing Director – Roche (rival)
Key Information
HQ – UK
Operations – Global
GlaxoSmithKline recently hit a 52-week high at 1852.40p on the 24th January. GSK have also licensed its tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for further development and potential use in countries with high TB burdens. Share price rose 0.4% in the past 30 days and is up 21% in the past 52 weeks.
Key Atheneum Experts
Former Senior Director – Gilead Sciences
Former Market Access Director – Bristol-Myers-Squibb (rival)
Former Global Marketing Director – Merck (rival)
Key Information
HQ – US
Operations – Global
Gilead Sciences share price has surged after it agreed to offer an experimental drug to combat coronavirus in China. In other news, Bristol-Myers Squibb have recently filed a motion asking federal judges to include punitive damages and royalties for Yescarta sales. This would raise Gilead’s penalty to $1.5bn following court orders last month to pay $752m in damages for infringing on patents. Share price fell 3.2% in the past 30 days and declined 6% over the past 52 weeks.
Key Atheneum Experts
Former Senior VP Market Access = Bayer
Former VP Marketing – Bayer
Senior Director Market Access – AstraZeneca
Key Information
HQ – Germany
Operations – Global
Bayer recently announced that it is donating medicines and financial aid worth around €1.5m to support the outbreak of coronavirus in China. In other news Bayer is expected to lead European pharma’s strong Q4 EPS reports with performance mirroring strong sales last quarter. Share price rose 1.3% in the past 30 days and up 10% in the past 52 weeks.
Key Atheneum Experts
Former Senior Director – Onconova Therapeutics
Former Regulatory Affairs Director – Onconova Therapeutics
Former Chief Business Officer – Catabasis Pharmaceuticals (rival)
Key Information
HQ – US
Operations – Global
Onconova Therapeutics recently said that it has regained drug rights in China after the company failed to make required payments as part of their licensing deal. The biopharmaceutical company focus on discovering and developing novel small molecule drug candidates to treat cancer. Share price fell 30% in the past 30 days and 90% over the past 52 weeks.
To learn more please email: yashar.jedari@atheneum-partners.com